Infectious Diseases Society of America: Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome Apr 22, 2022 COVID-19
PLOS Pathogens: Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species Mar 31, 2022 HIV
Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects Feb 28, 2022 HIV
Frontiers in Immunology: CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab Nov 19, 2021 HIV
Nature Communications: Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission Jun 7, 2021 HIV
Journal of Translational Autoimmunity: Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab Mar 16, 2021 COVID-19
Springer Nature: Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy Jan 23, 2021 Oncology
Journal of Translational Autoimmunity: Disruption of CCR5 Signaling to Treat COVID-19-Associated Cytokine Storm: Case Series of Four Critically Ill Patients Treated with Leronlimab Dec 30, 2020 COVID-19
International Journal of Infectious Diseases: CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14 Oct 30, 2020 COVID-19
Infectious Diseases Society of America: Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab Oct 20, 2020 COVID-19
